Corporate News     22-Jun-18
AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India
AstraZeneca Pharma India announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses.

Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab is a patented product of AstraZeneca global.

Previous News
  AstraZeneca slumps on recording dismal Q1 performance
 ( Hot Pursuit - 08-Aug-24   16:08 )
  Astrazeneca Pharma India reports standalone net loss of Rs 11.79 crore in the June 2024 quarter
 ( Results - Announcements 08-Aug-24   15:40 )
  Astrazeneca Pharma India fixes record date for final dividend
 ( Market Beat - Reports 26-Jun-24   09:51 )
  Astrazeneca Pharma India standalone net profit rises 128.60% in the March 2024 quarter
 ( Results - Announcements 28-May-24   07:37 )
  AstraZeneca Pharma India appoints director
 ( Corporate News - 13-Aug-20   10:21 )
  Astrazeneca Pharma India standalone net profit rises 3322.50% in the September 2017 quarter
 ( Results - Announcements 07-Nov-17   16:18 )
  Astrazeneca Pharma gets nod from CDSCO to import Olaparib film coated tablets
 ( Hot Pursuit - 22-Nov-23   11:07 )
  Astrazeneca Pharma India receives Import and Market permission for Osimertinib Tablet
 ( Corporate News - 09-Aug-18   10:47 )
  Astrazeneca Pharma India schedules AGM
 ( Corporate News - 18-Jul-20   17:12 )
  Astrazeneca Pharma India standalone net profit rises 10.17% in the June 2018 quarter
 ( Results - Announcements 15-Aug-18   13:44 )
  AstraZeneca UK decides to terminate distribution agreement for Meronem
 ( Corporate News - 24-Aug-16   17:32 )
Other Stories
  Tata Motors records 12% decline in Q2 sales
  01-Oct-24   18:04
  Tata Motors records 15% decline in September sales
  01-Oct-24   17:55
  Man Infra set to launch its highly anticipated Vile Parle project
  01-Oct-24   17:48
  Padam Cotton Yarns to declare Quarterly Result
  01-Oct-24   17:39
  Blueblood Ventures schedules board meeting
  01-Oct-24   17:39
  CRISIL to discuss results
  01-Oct-24   17:39
  Indian Renewable Energy Deve. Agency to convene board meeting
  01-Oct-24   17:39
  Ashapuri Gold Ornament schedules board meeting
  01-Oct-24   17:38
  Bijoy Hans to conduct board meeting
  01-Oct-24   17:38
  RS Software (India) to announce Quarterly Result
  01-Oct-24   17:38
Back Top